Medical devices are instruments, appliances or substances that are used in the biomedical field to diagnose, prevent, control or alleviate a disease, an injury, a handicap in order to ensure the patient’s safety. Over the last decade, thanks to technology evolution, a considerable amount of devices have been developed, resulting in a remarkable market expansion. For this very reason, legislation is currently working on how to incorporate every kind of medical device into regulations, with the main aim of protecting both the patient’s and the health worker’s health and safety. As a result of this growth in the field of medical devices and following the new European 745/2017 Regulation release, each country’s legislator inevitably has to pursue a European harmonization, so as to comply to the same features in production and marketing as those prescribed by regulation. Sedapeg, a medical device for children over two years of age with constipation, has been chosen as the subject of this study. Its technical dossier has been predictably affected by the recent regulatory change. Besides, Humana Pharma has managed to make Sedapeg suitable for children aged between six months and two years, by carrying out a comparative study and a research into literature that led to the decision of modifying Sedapeg dosage. This was accomplished ensuring both its safety and its efficacy.
I dispositivi medici sono strumenti, apparecchi o sostanze utilizzate in campo sanitario con lo scopo di diagnosticare, prevenire controllare o attenuare una malattia, una ferita, un handicap al fine di garantire la salute del paziente. Nell’ultimo decennio, grazie al progredire della tecnologia, si sono sviluppati innumerevoli dispositivi, con una notevole espansione del mercato. Proprio per questo la legislazione si sta occupando di normare al meglio tutto ciò che rientra come dispositivo medico, col principale scopo di tutelare la salute e la sicurezza del paziente e dell’operatore. Grazie a questa espansione in materia di dispositivi medici, è inevitabile che il legislatore, con la pubblicazione del nuovo regolamento europeo 745/2017 miri ad un’armonizzazione europea, con lo scopo rispettare le medesime caratteristiche per la produzione e la commercializzazione. Si è preso in considerazione Sedapeg, un dispositivo medico destinato ai bambini al di sopra dei 2 anni affetti da stipsi. Questo recente cambio normativo impatta inevitabilmente sul dossier tecnico del dispositivo medico. Oltre al cambio normativo avvenuto, Humana Pharma tramite un recente studio di comparazione e una ricerca bibliografica è riuscita a destinare Sedapeg di bambini dai 6 mesi a 2 anni tramite un cambio di posologia, garantendo sicurezza ed efficacia dello stesso.
Il nuovo regolamento sui dispositivi medici: il caso Sedapeg
OTTOLINI, LUCA
2016/2017
Abstract
Medical devices are instruments, appliances or substances that are used in the biomedical field to diagnose, prevent, control or alleviate a disease, an injury, a handicap in order to ensure the patient’s safety. Over the last decade, thanks to technology evolution, a considerable amount of devices have been developed, resulting in a remarkable market expansion. For this very reason, legislation is currently working on how to incorporate every kind of medical device into regulations, with the main aim of protecting both the patient’s and the health worker’s health and safety. As a result of this growth in the field of medical devices and following the new European 745/2017 Regulation release, each country’s legislator inevitably has to pursue a European harmonization, so as to comply to the same features in production and marketing as those prescribed by regulation. Sedapeg, a medical device for children over two years of age with constipation, has been chosen as the subject of this study. Its technical dossier has been predictably affected by the recent regulatory change. Besides, Humana Pharma has managed to make Sedapeg suitable for children aged between six months and two years, by carrying out a comparative study and a research into literature that led to the decision of modifying Sedapeg dosage. This was accomplished ensuring both its safety and its efficacy.È consentito all'utente scaricare e condividere i documenti disponibili a testo pieno in UNITESI UNIPV nel rispetto della licenza Creative Commons del tipo CC BY NC ND.
Per maggiori informazioni e per verifiche sull'eventuale disponibilità del file scrivere a: unitesi@unipv.it.
https://hdl.handle.net/20.500.14239/23707